FHA
AMPH icon

Flagship Harbor Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Flagship Harbor Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25
Closed -$670 – 792
2025
Q4 		$670 Buy
+25
New +$644 ﹤0.01% 1997
2018
Q3 		– Sell
-750
Closed -$11K – 2063
2018
Q2 		$11K Buy
+750
New +$13.1K ﹤0.01% 1316

Other funds holding AMPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return

Flagship Harbor Advisors's AMPH Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2026, closing a stake of 25 shares — an estimated $670 sold.

Flagship Harbor Advisors first reported a position in AMPH in Q2 2018 and held it in 2 quarters. The position peaked at $11K in Q2 2018. 215 funds tracked by Wall St. Rank hold AMPH as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining Amphastar Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 25 Amphastar Pharmaceuticals shares in Q1 2026, an estimated $670.
  • Flagship Harbor Advisors first reported a position in Amphastar Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Flagship Harbor Advisors's Amphastar Pharmaceuticals position peaked at $11K in Q2 2018.
  • 215 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.